Another type of therapy is based on obtaining and using monoclonal antibodies (mAbs) to surface proteins highly expressed in cancer cells, such as CD20 in lymphoma (rituximab), HER2 in breast cancer (trastuzumab), and epidermal growth factor receptor (EGFR) in colon cancer (cetuximab). This evidence concerns the gene ERBB2 and breast cancer.